RxDoctor Payments Data

Bruce Taylor

Adult Medicine · Selma, ALNPI 1760410849

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. That places this record below the midpoint for adult medicine clinicians in AL, where the typical reported total is $991.

$318in general payments, 2019–2025

Across 17 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$79
  • Novo Nordisk$52
  • AbbVie$50
  • Otsuka America Pharmaceutical, Inc.$43
  • Boehringer Ingelheim$34
  • Xeris Pharmaceuticals, Inc.$23
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 25th percentile of 26 adult medicine providers in Alabama.

See all adult medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$9,457
Medicare patients
28
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$84,159
MounjaroTirzepatide25$45,276
JardianceEmpagliflozin23$29,945
JanuviaSitagliptin Phosphate17$28,086
TrulicityDulaglutide26$24,853
GlyxambiEmpagliflozin/Linagliptin23$14,426
XareltoRivaroxaban15$11,935
Spiriva HandihalerTiotropium Bromide17$11,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,573
EliquisApixaban12$8,936
SymbicortBudesonide/Formoterol Fumarate13$2,953
Ibuprofen155$2,910
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine72$2,887
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid11$2,403
Acetaminophen-CodeineAcetaminophen With Codeine182$2,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$84,15966 claims
Boehringer IngelheimJardiance, Glyxambi$34$44,37146 claims
Johnson & JohnsonXarelto$20$11,93515 claims
AstraZenecaSymbicort$79$2,95313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 26 adult medicine providers in Alabama.

Other adult medicine in Selma

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →